Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aura Biosciences, Inc.AURA · Entity 5142 | SVP, Finance & PAO | September 01, 2026 | September 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aura Biosciences, Inc.
Report date September 01, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 143,600 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 23,540 · Balance 143,600 F1: The reported transaction represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock upon vesting and settlement. These RSUs shall vest in four substantially equal annual installments, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the first tranche vesting on September 15, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2036-09-01 | Direct | 46,460 |
Reported balance
After 2026-09-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-01 · Grant · Acquired 46,460 · Balance 46,460 F2: The stock option shall vest as to 1/48th of the total award monthly, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock upon vesting and settlement. These RSUs shall vest in four substantially equal annual installments, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the first tranche vesting on September 15, 2027.
F2: The stock option shall vest as to 1/48th of the total award monthly, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 1, 2026 21:23 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 46,460 | $0.00 Strike: $7.43 | $0.00 |
DisclosureSEC source: 0002042910-26-000003 · form4-09012026_090904.xml · derivative · entry 2 Elazzouzi Amy · CIK 0002042910 · SVP, Finance & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,460 Underlying: Common Stock · 46,460 shares Expires 2036-09-01 F2 · derivative.exercise_date: The stock option shall vest as to 1/48th of the total award monthly, subject to the reporting person's continued service to the Issuer on each vesting date, with the first tranche vesting on October 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 21:23 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 23,540 | $0.00 | $0.00 |
DisclosureSEC source: 0002042910-26-000003 · form4-09012026_090904.xml · nonDerivative · entry 1 Elazzouzi Amy · CIK 0002042910 · SVP, Finance & PAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,600 F1 · shares: The reported transaction represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock upon vesting and settlement. These RSUs shall vest in four substantially equal annual installments, subject to the Reporting Person's continued service to the Issuer on each vesting date, with the first tranche vesting on September 15, 2027. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:05 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 80,472 | $0.00 Strike: $6.14 | $0.00 |
DisclosureSEC source: 0001193125-26-088150 · ownership.xml · derivative · entry 2 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,472 Underlying: Common Stock · 80,472 shares Expires 2036-03-02 F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2027 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:05 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 44,528 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-088150 · ownership.xml · nonDerivative · entry 1 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,060 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on January 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 17, 2026 Filed Feb 18, 2026 00:47 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 8,549 | $5.06 | $43,257.94 |
DisclosureSEC source: 0001193125-26-055494 · ownership.xml · nonDerivative · entry 1 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,532 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.04 to $5.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 20, 2026 Filed Jan 20, 2026 23:41 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 1,581 | $4.86 | $7,683.66 |
DisclosureSEC source: 0001193125-26-016939 · ownership.xml · nonDerivative · entry 1 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,081 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| October 29, 2025 Filed Oct 29, 2025 21:05 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 896 | $6.35 | $5,689.60 |
DisclosureSEC source: 0001193125-25-256620 · ownership.xml · nonDerivative · entry 1 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,662 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:34 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,319 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0000950170-25-109767 · ownership.xml · derivative · entry 15 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,319 shares Expires 2030-03-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:34 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,094 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0000950170-25-109767 · ownership.xml · derivative · entry 14 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,094 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:34 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,744 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0000950170-25-109767 · ownership.xml · derivative · entry 13 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,744 shares Expires 2028-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:34 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionStock Option (Right to Buy) · Derivative | 547 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0000950170-25-109767 · ownership.xml · derivative · entry 12 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 547 shares Expires 2027-04-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:34 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionStock Option (Right to Buy) · Derivative | 547 | $0.00 Strike: $5.48 | $0.00 |
DisclosureSEC source: 0000950170-25-109767 · ownership.xml · derivative · entry 11 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 547 shares Expires 2026-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:34 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,094 | $0.00 Strike: $5.48 | $0.00 |
DisclosureSEC source: 0000950170-25-109767 · ownership.xml · derivative · entry 10 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,094 shares Expires 2026-04-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:34 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,554 | $0.00 Strike: $5.07 | $0.00 |
DisclosureSEC source: 0000950170-25-109767 · ownership.xml · derivative · entry 9 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,554 shares Expires 2025-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:34 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 7,722 | $6.70 | $51,737.40 |
DisclosureSEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 8 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,558 F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:34 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionCommon Stock | 2,319 | $4.25 | $9,855.75 |
DisclosureSEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 7 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:34 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionCommon Stock | 1,094 | $3.16 | $3,457.04 |
DisclosureSEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 6 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,961 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:34 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionCommon Stock | 4,744 | $2.74 | $12,998.56 |
DisclosureSEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 5 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,867 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:34 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionCommon Stock | 547 | $5.21 | $2,849.87 |
DisclosureSEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 4 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:34 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionCommon Stock | 547 | $5.48 | $2,997.56 |
DisclosureSEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 3 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:34 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionCommon Stock | 1,094 | $5.48 | $5,995.12 |
DisclosureSEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 2 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options. Read SEC document |
| August 18, 2025 Filed Aug 18, 2025 20:34 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | Exercise / conversionCommon Stock | 2,554 | $5.07 | $12,948.78 |
DisclosureSEC source: 0000950170-25-109767 · ownership.xml · nonDerivative · entry 1 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On August 18, 2025, the Reporting Person exercised long held stock options to purchase 12,899 shares of the Issuer's common stock, 7,722 of which were sold to cover the exercise price of such options. Read SEC document |
| April 16, 2025 Filed Apr 17, 2025 00:36 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 897 | $5.49 | $4,924.53 |
DisclosureSEC source: 0000950170-25-054954 · ownership.xml · nonDerivative · entry 1 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,381 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.49 to $5.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 00:31 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 1,404 | $7.75 | $10,881.00 |
DisclosureSEC source: 0000950170-25-022654 · ownership.xml · nonDerivative · entry 1 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,278 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:51 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 29,760 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0000950170-25-013825 · ownership.xml · derivative · entry 2 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,760 Underlying: Common Stock · 29,760 shares Expires 2035-02-02 F2 · derivative.exercise_date: The shares underlying this option vest as follows: 25% of the shares vest on February 3, 2026 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:51 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 45,240 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013825 · ownership.xml · nonDerivative · entry 1 Elazzouzi Amy · CIK 0002042910 · Senior Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,682 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in four substantially equal annual installments beginning on February 15, 2026, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 02:09 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 1,001 | $7.67 | $7,679.17 |
DisclosureSEC source: 0000950170-25-007494 · ownership.xml · nonDerivative · entry 1 Elazzouzi Amy · CIK 0002042910 · Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,442 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.67 to $7.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 29, 2024 Filed Oct 30, 2024 00:23 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | SaleCommon Stock | 553 | $10.74 | $5,938.39 |
DisclosureSEC source: 0000950170-24-118475 · ownership.xml · nonDerivative · entry 1 Elazzouzi Amy · CIK 0002042910 · Vice President, Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,443 F1 · kind: The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.65 to $10.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.